Welcome to Arakena Pharmaceuticals!
We are a Swiss biopharmaceutical start-up company focusing on novel cardiovascular therapies.
Cardiovascular Diseases are the leading cause of death globally, taking an estimated 18 million lives every year.
We want to change that.
More than four out of five cardiovascular deaths are due to heart attack and stroke.
One third of these deaths occur prematurely in people under 70 years of age.
That is why we founded Arakena
Arakena Pharmaceuticals was founded in 2024 by three scientists with a shared vision and decades of experience in pharma. Having already contributed to the development and approval of several successful medications, we teamed up to turn our passion for drug discovery into a company. Now, we’re bringing our know-how to the next chapter—science with purpose, built from experience.
Our Mission
Acute/chronic organ injuries often lead to disease progression and organ failure. We aim to protect organs and reverse the path to organ failure.
Our Vision
Create a world-leading biopharmaceutical company. Discover and develop novel, highly efficacious and safe compounds with life-saving potential in cardiovascular disease.
How we do it
In-license mid-staged discovery compounds: Validated concepts and potential for first-in-class and unmet medical need.
Use AI-assisted decision making tools: Rapidly identify efficacious compounds with excellent safety profile.
Value creation: Establish PCC-ready compound, demonstrate efficacy and MoA in models of target disease to initiate preclinical / clinical development.
1st Project identified: Exclusive option to license IP agreement with major US University.
What our experts say
“As a startup our goal is to launch innovation and make it market-ready, helping patients when they need it the most”
“By combining our passion for science with our more than 60 years of experience in the pharmaceutical industry, we will turn research into innovative medicines.”
“At Arakena, we have built a network of highly experienced experts and consultants who will help us bring our inventions to patients.“